Cardiotoxicity of Vasodilators and Positive Inotropic/Vasodilating Drugs in Dogs: An Overview
Authors:
- 1 January 1992
- journal article
- research article
- Published by Taylor & Francis in Critical Reviews in Toxicology
- Vol. 22 (3-4) , 203-241
Abstract
Standard toxicological studies in dogs using high doses of vasodilators and positive inotropic/ vasodilating agents give rise to a species-specific cardiotoxicity. The reason may be the extreme sensitivity of the dog to the pharmacological effects of these drugs; exaggerated pharmacodynamic effects and prolonged disturbance of homeostasis mechanisms often are responsible for the observed organ lesions. An assessment of the toxicological relevance and the risk for patients taking the drugs at therapeutic doses cannot be made without taking into account their pathomechanisms and the pathophysiological basis of the exceptional reaction patterns occurring in dogs. A large series of vasodilating and positive inotropic agents are presented, their pharmacological properties are described, and toxicological effects in dogs are compared. In view of the poor correlation between the distinct cardiac lesions induced in dogs and a lack of comparable toxicity in humans, it appears desirable to reassess the adequacy of the standard toxicological approaches for these substances.Keywords
This publication has 140 references indexed in Scilit:
- Nonsteroidal cardiotonics. 3. New 4,5-dihydro-6-(1H-indol-5-yl)pyridazin-3(2H)-ones and related compounds with positive inotropic activitiesJournal of Medicinal Chemistry, 1990
- Cardiovascular and biological effects of K+ channel openers, a class of drugs with vasorelaxant and cardioprotective propertiesLife Sciences, 1990
- Hemodynamically induced heart lesions in the dog after the administration of cardio-active substancesExperimental pathology, 1990
- The Value of Positive Inotropy in Acute and Chronic Heart FailureJournal of Cardiovascular Pharmacology, 1989
- Effects of Long-Term Therapy with Oral Piroximone on Resting Hemodynamics, Peak Aerobic Capacity, and the Anaerobic Threshold in Patients with Heart FailureJournal of Cardiovascular Pharmacology, 1987
- New Positive Inotropic Agents in the Treatment of Congestive Heart FailureNew England Journal of Medicine, 1986
- New Positive Inotropic Agents in the Treatment of Congestive Heart FailureNew England Journal of Medicine, 1986
- N″-cyano-N-4-pyridyl-N′-1,2,2-trimethylpropylguanidine, monohydrate (P 1134): A new, potent vasodilatorCellular and Molecular Life Sciences, 1980
- Myocardial Procainamide Concentration in Canine Atria and VentriclesJournal of Cardiovascular Pharmacology, 1979
- Assessment of the acute cardiotoxic potential of sodium nitroprusside infusions in Beagle dogsToxicology and Applied Pharmacology, 1978